AI-Powered Clinical Trial Site Feasibility Market Report 2026

The artificial intelligence (AI)-powered clinical trial site feasibility market size has grown exponentially in recent years. It will grow from $1.53 billion in 2025 to $1.89 billion in 2026 at a compound annual growth rate (CAGR) of 23.6%. The growth in the historic period can be attributed to increasing complexity of clinical trial designs, rising cost pressures on drug development timelines, growing reliance on data-driven trial planning, expansion of global multi-site clinical trials, early adoption of predictive analytics in trial feasibility.

The artificial intelligence (AI)-powered clinical trial site feasibility market size is expected to see exponential growth in the next few years. It will grow to $4.38 billion in 2030 at a compound annual growth rate (CAGR) of 23.3%. The growth in the forecast period can be attributed to increasing adoption of decentralized clinical trials, rising demand for faster site activation, growing use of real-world evidence in feasibility decisions, expansion of ai-enabled trial planning platforms, increasing emphasis on trial risk mitigation. Major trends in the forecast period include increasing adoption of AI-driven site selection models, rising use of predictive patient recruitment analytics, growing integration of real-world data in feasibility assessment, expansion of cloud-based feasibility platforms, enhanced focus on trial performance forecasting.

The growing number of clinical trials is expected to drive the expansion of the artificial intelligence (AI)-powered clinical trial site feasibility market in the coming years. Clinical trials are research studies conducted worldwide to evaluate the safety and efficacy of new treatments, drugs, and medical devices. The increase in clinical trials is primarily driven by rising investment in biomedical research and development, as both government and private sectors recognize the importance of innovative therapies to address healthcare challenges. This growth creates demand for AI-powered site feasibility tools, as research organizations require efficient systems to identify optimal trial locations, assess site capabilities, and predict enrollment success. For example, in April 2025, the Multidisciplinary Digital Publishing Institute reported that a total of 404,637 interventional clinical trials were listed on clinicaltrials.gov. Consequently, the expansion of clinical trials is fueling the growth of the AI-powered clinical trial site feasibility market.

Leading companies in the AI-powered clinical trial site feasibility market are focusing on developing advanced solutions, such as AI-driven feasibility and recruitment platforms, to optimize site selection and improve operational efficiency in clinical trials. These platforms leverage AI and machine learning to evaluate trial protocols and site data, identify the most suitable clinical sites, and enhance patient recruitment by matching eligible participants efficiently, accelerating trial timelines and improving study success. For instance, in June 2023, ObjectiveHealth, a US-based integrated research and technology company, launched ObjectiveScreen, an AI-powered feasibility and recruitment platform designed to optimize clinical trial performance. The platform improves patient identification, prequalification, and retention through real-time integration with electronic health records (EHRs) and AI algorithms, allowing clinical trial sites to stratify health risks and select the most qualified participants to accelerate enrollment and enhance trial outcomes.

In February 2023, ZS Associates, a US-based technology and management consulting firm, acquired Trials.ai for an undisclosed sum. This acquisition enables ZS Associates to strengthen its presence in the medical sector by improving clinical trial efficiency, accelerating therapy delivery to the market, and enhancing participant experience. Trials.ai is a US-based, healthcare-focused AI and analytics company that supports and enhances clinical trial site feasibility processes.

Major companies operating in the artificial intelligence (AI)-powered clinical trial site feasibility market are Oracle Corporation, Thermo Fisher Scientific Inc., NVIDIA Corporation, IQVIA Holdings Inc., Labcorp Holdings Inc., Dassault Systèmes SE, Parexel International Corporation, ZS Associates Inc., Veeva Systems Inc., Verily Life Sciences LLC, Signant Health Holding Corp., Saama Technologies LLC, Elligo Health Research Inc., ConcertAI Inc., Medable Inc., Science 37 Inc., Castor EDC Inc., Unlearn.AI Inc., Antidote Technologies Inc., Deep 6 AI.

North America was the largest region in the artificial intelligence (AI)-powered clinical trial site feasibility market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (AI)-powered clinical trial site feasibility market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI)-powered clinical trial site feasibility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the AI-powered clinical trial site feasibility market by increasing costs associated with imported computing hardware, data infrastructure components, and specialized analytics platforms used in advanced feasibility solutions. Pharmaceutical and contract research organizations in North America and Europe are most affected due to reliance on cross-border digital infrastructure and third-party technology providers, while Asia-Pacific faces pricing pressure on cloud-based analytics services. These tariffs are increasing operational costs and slowing technology upgrades. However, they are also encouraging localized data hosting, regional technology partnerships, and increased investment in domestic AI software development for clinical research.

The artificial intelligence (AI)-powered clinical trial site feasibility market research report is one of a series of new reports that provides artificial intelligence (AI)-powered clinical trial site feasibility market statistics, including artificial intelligence (AI)-powered clinical trial site feasibility industry global market size, regional shares, competitors with a artificial intelligence (AI)-powered clinical trial site feasibility market share, detailed artificial intelligence (AI)-powered clinical trial site feasibility market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-powered clinical trial site feasibility industry. This artificial intelligence (AI)-powered clinical trial site feasibility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI)-powered clinical trial site feasibility refers to services and platforms that use advanced algorithms to assess and select the most suitable clinical trial sites. These solutions analyze large datasets to predict site performance and patient recruitment potential, enhancing the speed and accuracy of decision-making while reducing the risk of trial delays. They streamline the feasibility process and improve overall operational efficiency.

The main components of AI-powered clinical trial site feasibility include software and services. The software consists of AI-driven digital platforms and tools that analyze trial data, site performance, and patient demographics to optimize site selection and feasibility. Deployment can be cloud-based or on-premises, with applications in site selection, patient recruitment, protocol design, performance analytics, and more. Key end-users include pharmaceutical companies, contract research organizations, academic research institutes, hospitals, and other healthcare and research organizations.

The artificial intelligence (AI)-powered clinical trial site feasibility market includes revenues earned by providing services such as site identification and selection, predictive enrollment modeling, investigator performance analysis, risk assessment and mitigation, and patient population analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.